SCHEMBL16468630

SCHEMBL16468630

CC(=O)Nc1cc(Oc2ccc(NC(=O)c3c(C)n(C)n(-c4ccccc4)c3=O)c(F)c2F)ccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.64
KDR P35968 17/20 0.64
IGF1R P08069 10/20 0.56
AURKA O14965 1/20 0.50
JAK2 O60674 1/20 0.50
RPS6KA5 O75582 1/20 0.50
ABL1 P00519 1/20 0.50
INSR P06213 1/20 0.50
LCK P06239 1/20 0.50
RET P07949 1/20 0.50
KIT P10721 1/20 0.50
PIM1 P11309 1/20 0.50
FGFR1 P11362 1/20 0.50
SRC P12931 1/20 0.50
PRKACA P17612 1/20 0.50
RPS6KB1 P23443 1/20 0.50
JAK1 P23458 1/20 0.50
MAPK3 P27361 1/20 0.50
AKT1 P31749 1/20 0.50
AKT2 P31751 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16437484 0.91 MET (0.78) METKDRIGF1RAURKAJAK2
SCHEMBL15559767 0.89 MET (0.68) METKDRIGF1RAURKAJAK2
SCHEMBL15559384 0.89 MET (0.64) METKDRIGF1RAURKAJAK2
SCHEMBL15560336 0.88 MET (0.77) METKDRIGF1RAURKAJAK2
SCHEMBL16468634 0.87 MET (0.59) METKDRIGF1RAURKAJAK2
SCHEMBL15559451 0.87 MET (0.67) METKDRIGF1RAURKAJAK2
SCHEMBL15558932 0.87 MET (0.83) METKDRIGF1RAURKAJAK2
SCHEMBL15559478 0.86 MET (0.66) METKDRIGF1RAURKAJAK2
SCHEMBL15558951 0.85 MET (0.69) METKDRIGF1RAURKAJAK2
SCHEMBL15560308 0.82 MET (0.85) METKDRIGF1RAURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2879676-B1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2017-06-14 EP disclosed
US-8969388-B1 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-03 US disclosed
US-8969388-B1 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-03 US disclosed
US-8969388-B1 Substituted pyrazolone compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-03 US disclosed
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-02-19 US disclosed
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-02-19 US disclosed
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150050239-A1 SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE MKI67, PRKACA, PRKDC MET 796/4885KDR 598/4885IGF1R 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.